Skip to main content
Fig. 7 | Biology Direct

Fig. 7

From: ANKRD29, as a new prognostic and immunological biomarker of non–small cell lung cancer, inhibits cell growth and migration by regulating MAPK signaling pathway

Fig. 7

ANKRD29 was a potential target for NSCLC treatment. A-B Representative IHC images of ANKRD29 in NSCLC tissue microarray. (B) Quantification data for (A), Scale bar = 100 μm. C-E NSCLC patients with low ANKRD29 expression had a worse prognosis examined by tissue microarray (C), KM plotter (D) and PrognoScan websites (E), respectively. F Volcano plot showed differentially expressed genes (DEGs) after overexpression of ANKRD29 expression by using RNA-seq analysis in H1975. G-H GO (G) and KEGG (H) analysis using DEGs enriched the pathways affected by upregulation of ANKRD29 expression. I Pearson correlation analysis was performed between ANKRD29 expression and drug IC50 using the GDSC database. J Molecular docking profiles of BEZ235-2 and AKT inhibitor VIII with ANKRD29. Bars are the mean value ± SD. ns = no significant. * P < 0.05, ** P < 0.01, *** P < 0.001

Back to article page

Biology Direct

ISSN: 1745-6150

Contact us